Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial

BACKGROUND: This study reports the findings of the first large-scale Phase III investigator-driven clinical trial to slow the rate of cognitive decline in Alzheimer disease with a dihydropyridine (DHP) calcium channel blocker, nilvadipine. Nilvadipine, licensed to treat hypertension, reduces amyloid...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:PLoS Med
Päätekijät: Lawlor, Brian, Segurado, Ricardo, Kennelly, Sean, Olde Rikkert, Marcel G. M., Howard, Robert, Pasquier, Florence, Börjesson-Hanson, Anne, Tsolaki, Magda, Lucca, Ugo, Molloy, D. William, Coen, Robert, Riepe, Matthias W., Kálmán, János, Kenny, Rose Anne, Cregg, Fiona, O'Dwyer, Sarah, Walsh, Cathal, Adams, Jessica, Banzi, Rita, Breuilh, Laetitia, Daly, Leslie, Hendrix, Suzanne, Aisen, Paul, Gaynor, Siobhan, Sheikhi, Ali, Taekema, Diana G., Verhey, Frans R., Nemni, Raffaello, Nobili, Flavio, Franceschi, Massimo, Frisoni, Giovanni, Zanetti, Orazio, Konsta, Anastasia, Anastasios, Orologas, Nenopoulou, Styliani, Tsolaki-Tagaraki, Fani, Pakaski, Magdolna, Dereeper, Olivier, de la Sayette, Vincent, Sénéchal, Olivier, Lavenu, Isabelle, Devendeville, Agnès, Calais, Gauthier, Crawford, Fiona, Mullan, Michael
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Public Library of Science 2018
Aiheet:
Research Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6152871/
https://ncbi.nlm.nih.gov/pubmed/30248105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1371/journal.pmed.1002660
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia